HC Wainwright reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a report published ...

Clearside Biomedical Inc. (CLSD)股价触及52周新低，跌至0.79美元。根据 InvestingPro 数据显示，尽管该公司资产超过短期负债，保持较强的流动性，但目前现金消耗速度令人担忧。这一最新价格水平反映出该专注于开发治疗致盲性疾病创新疗法的公司正经历显著下跌。过去一年，Clearside Biomedical股价下跌40.43%，表明这家生物科技公司正处于艰难时 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Clearside Biomedical, Inc. (CLSD) have been struggling lately and have lost 5.6% over the past two weeks. However, a hammer chart pattern was formed in its last trading session ...

CLSD opened at $0.93 on Monday. Clearside Biomedical has a fifty-two week low of $0.77 and a fifty-two week high of $2.12. The firm’s fifty day moving average price is $0.96 and its two-hundred ...

March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the ...

A downtrend has been apparent in Clearside Biomedical, Inc. (CLSD) lately with too much selling pressure. The stock has ...

Clearside Biomedical (CLSD) announced the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clearside Biomedical (CLSD – Research ...